Acute Lung Injury Market is estimated to reach at a CAGR of 5.8% during the forecast period (2024-2031).
Download Free Sample:
https://datamintelligence.com/download-sample/acute-lung-injury-market
Market Dynamics
The rising prevalence of pulmonary diseases is driving the acute pulmonary injury market. In Europe, COPD cases are projected to increase by 35.2% by 2050, while asthma affects 300 million people globally, with 96% of deaths in low- and middle-income countries. Tobacco use remains a major contributor, with 22.3% of the global population using it, leading to over 8 million deaths annually.
Market Segment
By Therapy: Mechanical ventilation, Pharmacotherapy, Fluid management
By End-user: Hospitals, Clinics, Others
Customize Your Sample:
https://datamintelligence.com/customize/acute-lung-injury-market
Market Geographical Share
The Asia-Pacific ethylene carbonate market is growing rapidly, driven by strong demand from China, India, Japan, South Korea, and Taiwan. Increasing industrialization, rising use of lithium-ion batteries, fuel cells, and surfactants, along with heavy investments in petrochemicals, are fueling market expansion. The region also sees rising demand for ethylene glycol, further boosting growth. Key players like Mitsubishi Chemical, INVESTCHEM, BASF SE, and Vertellus focus on new product development and regional expansion to strengthen their market position.
Market Key Player
Altor BioScience Corporation, GlaxoSmithKline Plc, Gilead Sciences Inc., Commence Bio, Inc., CompleGen, Inc., Histocell S.L., Windtree Therapeutics, Inc., Navigen Pharmaceuticals, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., and Ono Pharmaceutical Co., Ltd.
